Your browser doesn't support javascript.
loading
Nanovesicles released by OKT3 hybridoma express fully active antibodies.
Logozzi, Mariantonia; Di Raimo, Rossella; Properzi, Francesca; Barca, Stefano; Angelini, Daniela F; Mizzoni, Davide; Falchi, Mario; Battistini, Luca; Fais, Stefano.
Afiliação
  • Logozzi M; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • Di Raimo R; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • Properzi F; Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.
  • Barca S; FARVA - National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • Angelini DF; Neuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
  • Mizzoni D; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • Falchi M; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
  • Battistini L; Neuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
  • Fais S; Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.
J Enzyme Inhib Med Chem ; 36(1): 175-182, 2021 Dec.
Article em En | MEDLINE | ID: mdl-33404266
ABSTRACT
Recent findings have shown that nanovesicles preparations from either primary immune cells culture supernatants or plasma contain immunoglobulins, suggesting that a natural way of antibody production may be through exosome release. To verify this hypothesis, we used the OKT3 hybridoma clone, which produces a murine IgG2a monoclonal antibody used to reduce rejection in patients undergoing organ transplantation. We showed exosome-associated immunoglobulins in hybridoma supernatants, by Western blot, nanoscale flow cytometry and immunocapture-based ELISA. The OKT3-exo was also being able to trigger cytokines production in both CD4 and CD8 T cells. These results show that nanovesicles contain immunoglobulin and could be used for immunotherapy. These data could lead to a new approach to improve the effectiveness of therapeutic antibodies by exploiting their natural property to be expressed on nanovesicle membrane, that probably render them more stable and as a consequence more capable to interact with their specific ligand in the best way.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Linfócitos B / Linfócitos T / Muromonab-CD3 / Exossomos / Hibridomas Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Linfócitos B / Linfócitos T / Muromonab-CD3 / Exossomos / Hibridomas Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article